Prognosis Associated With Luminal and Basal Subtypes of Metastatic Prostate Cancer

CONCLUSIONS AND RELEVANCE: These findings represent the largest integrated clinical, transcriptomic, and genomic analysis of mCRPC samples to date, and suggest that mCRPC can be classified as luminal and basal tumors. Analogous to primary prostate cancer, these data suggest that the benefit of ASI treatment is more pronounced in luminal tumors and support the use of ASIs in this population. In the basal tumors, a chemotherapeutic approach could be considered in some patients given the similarity to SCNC and the diminished benefit of ASI therapy. Further validation in prospective clinical trials is warranted.PMID:34554200 | DOI:10.1001/jamaoncol.2021.3987

Source: Ann Oncol - September 23, 2021 Category: Cancer & Oncology Authors: Rahul Aggarwal Nicholas R Rydzewski Li Zhang Adam Foye Won Kim Kyle T Helzer Hamza Bakhtiar S Laura Chang Marc D Perry Martin Gleave Robert E Reiter Jiaoti Huang Christopher P Evans Joshi J Alumkal Joshua M Lang Menggang Yu David A Quigley Martin Sj östr Source Type: research